Feedback
OncLive®
AJMC®
Pharmacy Times®
Specialty Pharmacy Times
Specialty Pharmacy News

Express Scripts-Medco Decision Could Rely on Specialty Pharmacy Divisions

Randi Hernandez, Associate Editor/Online
Published Online: Thursday, March 29, 2012
The FTC’s approval of the highly publicized merger may depend on the divestiture of some of Medco’s assets.


Will prices increase across specialty pharmacy offerings if a larger PBM is able to dominate the marketplace through greater buying power?

Rumors are swirling that the Express Scripts-Medco merger will probably get a Federal Trade Commission (FTC) ruling on March 30, 2012, and "close the transaction as early as the week of April 2, 2012, subject to satisfaction or waiver of the remaining closing conditions," according to a Bloomberg report.

Some say the conditions in question pertain to selling off some of Medco’s specialty pharmacies in order for the FTC to allow the merger to go through. Medco and Express Scripts own the nation’s number 2 and number 3 specialty pharmacies, respectively—and many are worried that if joined, these 2 companies could use their leverage when acquiring distribution contracts from drug manufacturers.

According to an article in The Wall Street Journal, the FTC could also prevent the merged entity from requiring that large employers and insurers use the combined company’s specialty pharmacies.

Spending in specialty is rising, and as previously reported, Express Scripts-Medco would control 52% of the specialty drug market if their merger is approved. The new company would be 3 times the size of its nearest competitor.

Supporters of the merger claim that the combined efforts of Medco and Express Scripts could actually put more pressure on the specialty drug manufacturers to lower their prices. Lowell Weiner, a Medco spokesman, told The Wall Street Journal that a partnership between the companies could “further reduce the cost of providing specialty-pharmacy care for our clients and their members.”

For more information:

Further Reading
Express Scripts Senior Clinical Consultant Aimee Tharaldson, PharmD, discusses specialty pharmacy treatment options for 2014 and beyond.
Aimee Tharaldson of Express Scripts explains why some hepatitis C patients who do not have signs of active disease may want to wait to receive treatment until later this year and early next year, when the FDA is expected to approve sofosbuvir and simeprevir for the treatment of this condition.
Last year there were 11 new cancer drugs approved, and so far this year, 6 oncology medications have been approved, notes Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts.
Pharmacy Times
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Pharmacy Times 2006-2013
Intellisphere, LLC. All Rights Reserved.